Actelion

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Actelion sits in the top decile of US sponsors by registered trial count (#328 of 15,742 sponsors by registered trial count).

63 total trials none currently recruiting 43 completed top decile by trial count

Actelion: 63 sponsored US clinical trials, none currently recruiting.

Actelion sponsors 63 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 43 completed. 34 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Arterial Hypertension, with 7 trials.

Top-decile sponsor footprint

Actelion ranks in the top decile of sponsors by registered trial count (#328 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 18/100

43 of 60 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

63 total, page 1 of 2

ACTIVE NOT RECRUITING Phase 3

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04273945
ACTIVE NOT RECRUITING Phase 3

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04175600
ACTIVE NOT RECRUITING Phase 2

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

NCT03492177
COMPLETED Phase 1

A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist

NCT05427162
COMPLETED Phase 1

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

NCT05236231
TERMINATED Phase 4

A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants

NCT04955990
TERMINATED Phase 4

A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging

NCT04435782
TERMINATED Phase 2

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

NCT03942211
TERMINATED Phase 3

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

NCT04271475
COMPLETED Phase 3

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT03904693
TERMINATED Phase 3

An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.

NCT03775421
TERMINATED Phase 3

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

NCT03689244
TERMINATED Phase 2

A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

NCT03714815
COMPLETED Phase 3

Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

NCT03187678
COMPLETED Phase 4

Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

NCT03078907
COMPLETED Phase 3

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

NCT02932410
COMPLETED Phase 3

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

NCT03153137
COMPLETED

Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States

NCT03197688
COMPLETED Phase 2

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

NCT03153111
COMPLETED Phase 3

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

NCT03232073
TERMINATED Phase 2

Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)

NCT03105479
TERMINATED Phase 3

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

NCT02907177
COMPLETED

A Registry for Patients Taking Uptravi

NCT03278002
COMPLETED Phase 3

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

NCT02558231
COMPLETED Phase 2

Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation

NCT02554903
COMPLETED Phase 3

Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension

NCT02471183
COMPLETED Phase 4

PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

NCT02382016
COMPLETED Phase 3

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

NCT02425644
COMPLETED Phase 4

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension

NCT02310672
TERMINATED Phase 1

Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma

NCT02254954
COMPLETED Phase 2

Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

NCT02070991
COMPLETED

OPsumit USers Registry

NCT02126943
TERMINATED Phase 3

Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

NCT01739400
TERMINATED Phase 3

Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument

NCT01847014
COMPLETED Phase 3

Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

NCT01743001
COMPLETED Phase 3

Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

NCT01841762
COMPLETED Phase 1

Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects

NCT02206204
TERMINATED Phase 2

Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)

NCT01437878
TERMINATED Phase 1

Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

NCT01499251
COMPLETED Phase 3

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

NCT01474109
COMPLETED Phase 1

Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects

NCT02136888
COMPLETED

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

NCT01389206
COMPLETED Phase 3

FUTURE 3 Study Extension

NCT01338415
COMPLETED Phase 2

Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)

NCT01222702
COMPLETED Phase 3

ACT-293987 in Pulmonary Arterial Hypertension

NCT01112306
COMPLETED Phase 2

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

NCT01093326
COMPLETED Phase 4

Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401

NCT01105117
COMPLETED Phase 3

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

NCT01106014
COMPLETED Phase 2

Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

NCT01006265
COMPLETED Phase 2

Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study

NCT00903331
Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 16
Phase 3 27
Phase 4 7

Therapeutic Areas

Pulmonary Arterial Hypertension 7
Cardiodynamics 1
Safety 1
Hypertension, Pulmonary 1
Clostridium Difficile Infection 1
Idiopathic Pulmonary Fibrosis 1
Pharmacokinetics 1
Tolerability 1
Pulmonary Hypertension 1
Multiple Sclerosis 1

How the Actelion archive is shaped

63 indexed studies, none listed as recruiting (0% open); 43 completed (68%).

Phase mix: 34 late (III/IV) vs 23 early (I/II) (balanced across stages).

Top condition: Pulmonary Arterial Hypertension (7 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Actelion: archived-pipeline peers nationwide

Peers matched on 63 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Actelion sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080 0%5%10%15%20% Total trials Recruiting share ActelionHennepin Healthcare Research InstituteUnited TherapeuticsUniversity of OregonCephalon10xBio22nd Century Group23andMe3-C Institute for Social Development
Actelion sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Actelion sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 63 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Actelion page

63 registered trials is a research-attention snapshot, not an endorsement of Actelion or any single study.

  • None of Actelion's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Pulmonary Arterial Hypertension is the condition Actelion studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Arterial Hypertension trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Actelion pipeline card: 63 registered trials from official public datasets.Report a data error.